On 9 October 2019 PlumeSTARS will actively participate at the fourth edition of the Italian Innovation Day that will be held in Tokyo, together with other promising start-ups on the international scene.

There will be pitching, demonstrations and great presentations, with take-aways for both investors and innovation driven organizations.

Keynote speaker will be the startup journalist Emil Abirascid and supporter of the Italian Innovation Day since the first edition. He will tell us about the latest trends in the Italian startup and venture capital ecosystem, analyse current situation and identify cooperation and investment opportunities for Japanese corporations.

Masaru Ikeda, supporter of the event since 2017, will be Master of Ceremony together with Emil Abirascid. Startup journalist and experienced moderator, he will treat us with insightful comments and valuable questions to the speakers.

An exciting occasion to know about the Italian startup ecosystem and the investment and business opportunities it offers.

Italian startups pitching their ideas, business experts introducing the Italian startup ecosystem and VC industry, guest speakers giving precious insights.

For more information:

PlumeSTARS actively contributed to the 5 th International TB Meeting inhaled therapies for tuberculosis and other infectious diseases

Prof. Paolo Colombo, CEO of PlumeSTARS and Dr. Eride Quarta, Research Scientist of PlumeSTARS, attended the 5th International TB Meeting “Inhaled therapies for tuberculosis and other infectious diseases” in Groningen (The Netherlands) from 25 to 27 August 2019.

Prof. Paolo Colombo, as chairman, opened the First Session on formulations and devices, saying that Integrating the tuberculosis systemic drug administration with targeted loco-regional treatment improves the therapy effectiveness. The congress proposal in this direction was to introduce the administration of anti-bacterial drugs by inhalation as an adjunct to systemic therapy. This strategy allows a direct attack to the Mycobacterium tuberculosis, i.e., the disease responsible.

Pulmonary drug products, in particular the most technologically advanced dry powders inhalers, imply a demanding pharma-tech development, since numerous variables for controlling the deposition of drug particles are involved. Bronchial or alveolar regions are the targets of TB disease.

The powders for inhalation are essentially formulated by crushing drug particles by milling or by constructing ex novo microparticulate shapes. In general, in infective lung diseases, the products present a high amount of powder to inhale for dose administration. In addition, in TB, more than one drug has to be delivered at same time. This forces the device technologies for metering, aerosolization and deposition to be strongly innovative.

In summary, formulation and device for anti-TB dry powder inhalation products are not simple combination products. Their sophistication is essential to facing the interaction among product, patient and microbial target. Local concentration of antibiotics, retention time and compliance with daily dosing could also suggest compounding of prolonged release formulations, using colloidal particles and controlling dissolution rate using compatible safe polymers. Therefore, novel inhaled antibiotic formulations, such as dry powder for inhalation, are promising as problem solving drug composition.

Finally, also Dr. Eride Quarta,research scientist of PlumeStars and PhD student of Department of Food& Drug at Parma University, presented the research contribution“Microparticles embedding streptomycin sulfate and isoniazid albumin co-nanoparticles for dry powder inhalers”.